SEC 13F Intelligence

Managers / Q2 2023 · view latest →

Altium Capital Management LLC

CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711

Reported Value
$132M
Q2 2023
Positions
68
Filings on Record
25
2019–present window
Filed
Aug 14, 2023
original filing

Summary

Altium Capital Management LLC reported $132M in U.S.-listed holdings across 68 positions for Q2 2023.

Its largest position, Chinook Therapeutics, represents 8.9% of the portfolio.

Compared with Q1 2023, the fund opened 19 new positions and exited 42.

Portfolio Metrics

Turnover
+46.1%
vs prior filed quarter
Top-10 Concentration
+58.7%
share of reported value
Largest Position
+8.9%
Chinook Therapeutics
New / Exited
19 / 42
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $266MQ4 ’20Q1 ’21: $360MQ2 ’21: $431MQ3 ’21: $381MQ3 ’21Q4 ’21: $363MQ1 ’22: $299MQ2 ’22: $250MQ2 ’22Q3 ’22: $273MQ4 ’22: $197MQ1 ’23: $180MQ1 ’23Q2 ’23: $132MQ3 ’23: $192MQ4 ’23: $147MQ4 ’23Q1 ’24: $253MQ2 ’24: $245MQ3 ’24: $340MQ3 ’24Q4 ’24: $353MQ1 ’25: $42MQ2 ’25: $0Q2 ’25Q3 ’25: $628,262Q4 ’25: $25MQ1 ’26: $42MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 84.2%Other: 14.5%Equity WRT: 0.8%ADR: 0.4%
  • Common Stock · 84.2% · $111M
  • Other · 14.5% · $19M
  • Equity WRT · 0.8% · $1M
  • ADR · 0.4% · $582,583

Quarter-over-Quarter Changes full breakdown →

vs Q1 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
IMMUNOGEN INCNEW+485.0K485.0K+$9M$9M
XENEXENON PHARMACEUTICALS INCNEW+228.0K228.0K+$9M$9M
GRI BIO INCNEW+1.18M1.18M+$5M$5M
MLTXMOONLAKE IMMUNOTHERAPEUTICSNEW+88.0K88.0K+$4M$4M
JASPER THERAPEUTICS INCNEW+2.87M2.87M+$4M$4M
INTERCEPT PHARMACEUTICALS INNEW+323.0K323.0K+$4M$4M
BRIDGEBIO PHARMA INCNEW+200.0K200.0K+$3M$3M
SRPTSAREPTA THERAPEUTICS INCNEW+28.0K28.0K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2023

58 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CHINOOK THERAPEUTICS INCCOM8.87%$12M305.0K
2ASTRIA THERAPEUTICS INCCOM8.49%$11M1.35M
3IMMUNOGEN INCCOM6.93%$9M485.0K
4ADMAADMA BIOLOGICS INChistory →COM6.65%$9M2.38M
5XENEXENON PHARMACEUTICALS INChistory →COM6.64%$9M228.0K
6CYMABAY THERAPEUTICS INCCOM5.54%$7M668.7K
7XTNTXTANT MED HLDGS INChistory →COM NEW4.38%$6M6.23M
8HRMYHARMONY BIOSCIENCES HLDGS INhistory →COM3.99%$5M149.9K
9GRI BIO INCCOM3.79%$5M1.18M
10MLTXMOONLAKE IMMUNOTHERAPEUTICShistory →CLASS A ORD3.40%$4M88.0K
11REATA PHARMACEUTICALS INCCL A3.20%$4M41.5K
12AMLXAMYLYX PHARMACEUTICALS INChistory →COM3.02%$4M185.0K
13JASPER THERAPEUTICS INCCOM2.97%$4M2.87M
14INTERCEPT PHARMACEUTICALS INCOM2.70%$4M323.0K
15SRPTSAREPTA THERAPEUTICS INChistory →COM2.43%$3M28.0K
16REPLREPLIMUNE GROUP INChistory →COM2.28%$3M130.0K
17PHATPHATHOM PHARMACEUTICALS INChistory →COM2.25%$3M207.4K
18AXSMAXSOME THERAPEUTICS INChistory →COM2.18%$3M40.0K
19OLMAOLEMA PHARMACEUTICALS INChistory →COM2.12%$3M310.0K
20COGTCOGENT BIOSCIENCES INChistory →COM2.11%$3M235.0K
21CRNXCRINETICS PHARMACEUTICALS INhistory →COM1.84%$2M135.0K
22VERAVERA THERAPEUTICS INChistory →CL A1.46%$2M120.0K
23DYNDYNE THERAPEUTICS INChistory →COM1.32%$2M155.0K
24PRAXIS PRECISION MEDICINES ICOM1.24%$2M1.43M
25KARYOPHARM THERAPEUTICS INCCOM1.00%$1M740.0K
26PEPPERLIME HEALTH ACQUSTN COCLASS A ORD SHS · *W EXP 10/01/2020.80%$1M467.5K
27CYCUWWESTERN ACQSTN VENTURES CORPCOM · *W EXP 09/01/2020.79%$1M200.0K
28KODKODIAK SCIENCES INCCOM0.78%$1M150.0K
29FAT BRANDS INC*W EXP 07/16/2020.59%$776,340227.0K
30IMVTIMMUNOVANT INCCOM0.50%$665,84735.1K
31POLISHED COM INC*W EXP 06/02/202 · COM0.50%$661,1206.68M
32DDIDOUBLEDOWN INTERACTIVE CO LTADS0.44%$582,58360.9K
33COLOMBIER ACQUISITION CORPCL A · *W EXP 99/99/9990.40%$526,29166.7K
34OPY ACQUISITION CORP ICOM CL A · *W EXP 09/22/2020.39%$516,255100.0K
35WEARABLE DEVICES LTD*W EXP 09/14/2020.21%$282,3201.41M
36MRAIMARPAI INCCL A COM NEW0.15%$201,520117.8K
37DIRECT DIGITAL HOLDINGS INC*W EXP 02/15/2020.08%$108,000180.0K
38NXGLWNEXGEL INC*W EXP 12/01/2020.07%$97,200225.0K
39NOCTURNE ACQUISITION CORPRIGHT 12/26/20250.05%$62,550500.0K
40CINGWCINGULATE INC*W EXP 12/10/2020.04%$56,700270.0K
41JEFFS BRANDS LTD*W EXP 08/26/2020.04%$55,721480.8K
42ONFOWONFOLIO HOLDINGS INC*W EXP 01/02/2020.03%$40,000200.0K
43BRSWFBRUUSH ORAL CARE INC*W EXP 08/03/2020.02%$28,846360.6K
44NLS PHARMACEUTICS LTD*W EXP 02/02/2020.02%$21,400200.0K
45BNCWWCEA INDUSTRIES INC*W EXP 02/11/2020.01%$13,188250.0K
46PROSOMNUS INC*W EXP 04/20/2020.01%$12,075150.0K
47NEXALIN TECHNOLOGY INC*W EXP 09/15/2020.01%$11,550105.0K
48DIGITAL HEALTH ACQUISITION C*W EXP 11/02/2020.01%$9,990150.0K
49HARBOR CUSTOM DEVELOPMENT IN*W EXP 10/07/202 · *W EXP 05/09/2020.01%$9,9201.25M
50CHAVANT CAPITAL ACQUISITN CO*W EXP 99/99/9990.00%$6,450150.0K
51MURPHY CANYON ACQUISITION CO*W EXP 01/25/2020.00%$4,580100.0K
52SRZNWSURROZEN INC*W EXP 08/01/2030.00%$4,53982.2K
53TG VENTURE ACQUISITION CORP*W EXP 08/15/2020.00%$4,500200.0K
54SELINA HOSPITALITY PLC*W EXP 10/27/2020.00%$4,331101.4K
55COLISEUM ACQUISITION CORP*W EXP 08/22/2020.00%$4,24728.3K
56LIGHTNING EMOTORS INC*W EXP 05/18/2020.00%$99132.6K
57TCBWFTC BIOPHARM HOLDINGS PLC*W EXP 02/08/2020.00%$80918.8K
58RELATIVITY ACQUISITION CORP*W EXP 12/15/2020.00%$0100.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$42M19May 1, 202613F-HRchanges · EDGAR ↗
Q4 2025$25M18Feb 6, 202613F-HRchanges · EDGAR ↗
Q3 2025$628,2621Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$42M24May 13, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$353M67Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$340M79Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$245M68Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$253M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$147M66Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$192M72Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$132M68Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$180M91May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$197M94Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$273M134Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$250M127Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$299M118May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$363M133Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$381M124Nov 17, 2021RESTATEMENTchanges · EDGAR ↗
Q2 2021$431M135Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$360M124May 6, 202113F-HRchanges · EDGAR ↗
Q4 2020$266M98Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.